EUROPEAN SOCIETY OF RADIOLOGY
Insights into Imaging

CRITICAL REVIEW

Post-treatment surveillance imaging in head and neck cancer: a systematic review

Stefaan Van Hoe[1] and Robert Hermans[2,3]*

Abstract

Background In patients treated for head and neck cancer, imaging studies are usually obtained within 3–6 months after treatment for assessment of treatment response. After 6 months, most guidelines advocate clinical follow-up, with imaging reserved for patients with clinically suspect or equivocal findings. However, some guidelines do recommend systematic imaging surveillance, and many clinicians tend to include some type of imaging in their follow-up schemes.

Objectives This systematic review focuses on the usefulness of routine (systematic) post-treatment imaging surveillance of head and neck cancer beyond the first 3–6-month baseline imaging study.

Methods A systematic literature search was conducted using PubMed and Google Scholar. Additional studies were identified by reviewing reference lists. Only original studies and review papers were considered. Results obtained with systematic post-treatment surveillance imaging were compared to symptom-directed imaging and/or clinical finding-directed imaging.

Results Five hundred twenty-one records were identified through the database search, and 44 additional records were identified through other sources. Forty-eight articles were selected for the final review.

Analysis of these records showed that almost half of cases of locoregional recurrences and/or metastases were only detected by imaging (40.9%), and the mean time of detection of recurrent or metastatic disease (11.5 months) was well beyond the period of the first post-treatment scan. Most authors reported superior results with PET-CT when compared to other imaging techniques.

Conclusion Strong arguments were found in favor of systematic imaging surveillance in locoregional advanced head and neck cancer during at least one and preferably 2 years after treatment.

Critical relevance statement Analysis of the selected records showed that almost half of cases of locoregional recurrences and/or metastases were only detected by imaging. This systematic review suggests that imaging may currently be underused in the post-treatment surveillance of patients with head and neck cancer.

Key points

• This systematic review focuses on the usefulness of long-term systematic imaging surveillance in patients treated for head and neck cancer.

• Analysis of 521 articles revealed that systematic imaging allowed the initial detection of locoregional recurrences and/or metastases in more than 40% of patients.

• Imaging may currently be underused in the post-treatment surveillance of patients with advanced head and neck cancer.

*Correspondence:
Robert Hermans
robert.hermans@uzleuven.be
Full list of author information is available at the end of the article

Springer Open

Graphical Abstract

Introduction

Worldwide head and neck cancer accounts for approximately 900,000 cases and over 400,000 deaths annually [1]. Most malignant tumors are head and neck squamous cell carcinomas (HNSCC). Treatment options include surgery, radiation therapy, and chemotherapy, or a combination of these modalities.

Approximately 50% of patients with locally advanced head and neck cancer will develop a recurrence [2, 3]. Distant metastases are present in about 10% of cases at the time of diagnosis, with an additional 20–30% developing during the course of the disease [4]. Up to 80–85% of metastases from HNSCC are observed in the lungs. Bone metastases account for 15–39%, while the liver is affected in 10–30% of cases.

Patients treated for primary HNSCC also have a high rate (3 to 5% per year) of developing second primary tumors [5, 6].

After treatment, there are two principal periods of surveillance: immediate posttreatment (within 6 months) and long-term (6 months onward).

There is now a consensus that, for patients with locoregionally advanced disease (e.g., T3-T4 primary or N1+nodal staging), imaging should be performed within 3 months to 6 months after completion of definitive treatment in order to assess treatment response [7–9].

On the other hand, the utility of long-term imaging surveillance is subject of debate. Currently, controlled prospective data demonstrating a survival benefit for any follow-up strategy in this specific context do not exist. While some guidelines recommend systematic imaging, others state that additional post-treatment imaging should be reserved for patients with worrisome or equivocal signs and/or symptoms [8–17]. The National Comprehensive Cancer Network (NCCN), for instance, does not recommend routine imaging for surveillance in asymptomatic patients, except for specific patient populations. These include patients with primary nasopharyngeal carcinoma, a history of smoking, or a primary tumor in areas inaccessible by clinical examination [8].

Surveys of practicing physicians have shown that many clinicians do not follow the NCCN guidelines and believe systematic imaging may be appropriate in at least some of their patients, despite lack of symptoms [18–20]. In other words, current guidelines are inconsistent and contradictory, and clinicians tend to develop their own strategy, based on personal and institutional preference.

This systematic review exclusively focuses on the usefulness of routine post-treatment imaging of head and neck cancer beyond the first 3–6-month baseline imaging study. Hereby, the strategy of systematic follow-up imaging is compared to symptom-directed imaging and/or clinical finding-directed imaging. This is an important issue because both overuse and underuse of imaging bears significant risk and disadvantages. Overuse of imaging may cause patient stress, unnecessary expenses [21] and iatrogenic side effects (e.g., related to radiation in CT or PET/CT). Underuse of imaging, on the other hand, may lead to missed opportunities for early detection of recurrences and salvage treatment.

In this study, we review the retrospective data and observational studies that are available. Possible outcomes studied are the detection of locoregional recurrence or metastases, change of therapeutic regimen, and survival. The focus is on squamous cell carcinoma of the pharynx, oral cavity, and larynx. Both qualitative and quantitative results are obtained, and the collected data are used to provide practical recommendations.

Methods
Study protocol and registration
Methods of the analysis and inclusion criteria were specified in advance and documented in a protocol accordingly to the PRISMA guidelines [22, 23].

Eligibility criteria
Study eligibility criteria are given below according to the PICOS framework (populations, interventions, comparators, outcomes, and study designs of interest) as well as other study-specific elements.

(1) Types of participants/populations (**P**): patients who underwent treatment for head and neck cancer, with curative intent. Further inclusion criteria:

- Squamous cell carcinoma
- Primary tumor in nasopharynx, oropharynx, hypopharynx, larynx, or oral cavity
- Patients treated with surgery, radiotherapy, and/or systemic therapy
- Patients with or without risk factors (smoking etc.)

(2) Types of intervention (**I**): systematic (planned) post-treatment surveillance imaging studies.

- This review does not cover the first post-treatment scan, typically performed after 3–6 months
- Included are studies on post-treatment imaging surveillance after the first post-treatment scan
- Techniques: computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), PET-CT, ultrasonography (US)
- Body locations studied: neck, chest, and/or full body
- Search for local recurrence, regional recurrence (e.g., lymph nodes in the neck), distant metastases

(3) Types of comparators (**C**): other methods used for detection of locoregional recurrence or metastases.

- Clinical exam
- Patient anamnesis (symptoms)
- Imaging studies requested based on suspect clinical exam of patient symptoms (in contrast to systematic—planned—imaging surveillance)
- Endoscopic studies
- Other types of imaging studies (e.g., PET-CT versus CT)
- Any other test

(4) Types of outcome measures (**O**):

- Detection of local recurrence, regional recurrence (e.g., metastatic lymph nodes), distant metastases
- Change in therapeutic regimen
- Impact on survival

(5) Types of studies (**S**):

- Included: original studies, abstracts of conference papers (if containing sufficiently detailed information), doctoral dissertations
- Excluded: letters, editorials, reviews, and case reports

- Studies can be prospective or retrospective. Studies using mathematical models (e.g., Markov models) were also included

(6) Other study-specific elements:

- Reports published before 2000 were not considered during the initial search
- Report language was restricted to English, French, and Dutch
- Only published reports were considered
- No restriction was put on the length of follow-up

Information sources

PubMed and Google Scholar were used for database search. The PubMed and Google Scholar search was done between August 1 and September 27, 2022. The search was developed and conducted by SVH.

Supplementary approaches to identify studies are as follows: first, the reference lists of all review articles obtained via the database search described above were checked, and additional records fulfilling the eligibility criteria were identified. Next, all articles citing the records found via the database search described above were identified via Google Scholar. Next, the reference list of the article "Posttreatment surveillance of squamous cell carcinoma of the head and neck" in the electronic database "*UpToDate*" was checked. Finally, the reference lists of the articles obtained via the last two steps were scrutinized.

Electronic database search strategy

The following searches were done:

- PUBMED SEARCH: ((head and neck cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (imaging[Title/Abstract])
- PUBMED SEARCH: ((head and neck cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (posttreatment[Title/Abstract])
- References in NCCN guidelines
- PUBMED SEARCH: ((head and neck cancer[Title/Abstract]) AND (follow-up[Title/Abstract])) AND (posttreatment[Title/Abstract])
- PUBMED SEARCH: ((head and neck cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (tomography[Title/Abstract])
- PUBMED SEARCH: (((cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (imaging[Title/Abstract])) AND (pharynx)

- PUBMED SEARCH: (((cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (imaging[Title/Abstract])) AND (oral cavity[Title/Abstract])
- PUBMED SEARCH: (((cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (imaging[Title/Abstract])) AND (larynx[Title/Abstract])
- GOOGLE SCHOLAR SEARCH: "head and neck cancer posttreatment imaging surveillance"
- GOOGLE SCHOLAR SEARCH: "head and neck cancer posttreatment imaging follow-up"
- GOOGLE SCHOLAR SEARCH: "pharynx cancer imaging surveillance"
- GOOGLE SCHOLAR SEARCH: "oral cavity cancer imaging surveillance":
- GOOGLE SCHOLAR SEARCH: "larynx cancer imaging follow-up surveillance":
- GOOGLE SCHOLAR SEARCH: "head and neck cancer tomography surveillance":
- GOOGLE SCHOLAR SEARCH: all articles citing the records found via the database search described above were identified via Google Scholar ("cited by").
- UPTODATE: the reference list of the article "Posttreatment surveillance of squamous cell carcinoma of the head and neck" [24] in the electronic database "UpToDate" was checked.

Study selection

Eligibility assessment was performed by one author (S.V.H.) and reviewed by a second author (R.H.). Records obviously not covering the topic of the review were excluded from further consideration. Disagreements between reviewers were resolved by consensus.

Records obtained from the PubMed and Google Scholar searches were compared, and duplicates were removed. Records obtained via the supplementary approaches to identify studies (see above) were only retained if the record was not yet available in the list of records obtained via database search (i.e., duplicates were removed on a record-by-record basis).

All records obtained via the database search and via the supplementary approaches were screened based on evaluation of title and abstract. Inclusion and exclusion criteria are described above in accordance with the PICOS framework.

The potentially eligible records not excluded during this step were promoted to the next stage of the review: full text screening (see Fig. 1). All articles selected for full text review were read by one author (S.V.H.). This work was reviewed by RH and discrepancies were resolved in consensus.

During all steps in the process, special attention was given to the removal of duplicate studies.

Fig. 1 PRISMA flowchart

The details of each article (author, title, publication year) were recorded in an excel file. In the file, each article was assigned to one of the following categories, in accordance with the methodology described above:

- Category 1: Record obtained via database search or via the supplementary approaches but excluded based on evaluation of title and abstract
- Category 2: Records considered eligible based on review of title and abstract but excluded after full text review
- Category 3: Records included after full text review

An overview of all articles, together with their category, is given in the electronic supplementary material (Manuscript selection sheet).

In addition to the reasons given above, reasons to exclude articles were as follows:

- Missing details in the materials and methods or results section, making interpretation or data extraction difficult or impossible
- Full text article not accessible
- Different research topic than anticipated based on reading the title and abstract
- No comparison between systematic (routine) surveillance imaging and another type of surveillance (presentation of results obtained with one method, without any comparison)

The records that were selected for qualitative review were divided in one or more of the following categories:

- Results obtained in a group of patients with different types of head and neck cancer (different in terms of primary location)
- Results obtained in a subgroup of patients with oropharyngeal cancer
- Results obtained in a subgroup of patients with cancer of the oral cavity
- Results obtained in a subgroup of patients with cancer of the hypopharynx/larynx
- Results for comparison of imaging techniques

In addition, records referring to guidelines pertinent to post-treatment surveillance of head and neck tumors were identified.

Data collection process

We developed a data extraction sheet, pilot-tested it on ten randomly selected included studies, and used it accordingly (see Manuscript selection sheet). Data extraction was done by one author (S.V.H.) and reviewed by RH. Discrepancies were resolved in consensus.

Extracted data items

The following quantitative data were extracted if available:

- Percentage of locoregional recurrences/metastases observed more than 6 months after treatment
- Average time of detection of locoregional recurrences/metastases (months after the end of treatment)

- Percentage of locoregional recurrences/metastases detected by surveillance imaging versus other methods

Presentation of results

For clarity, results are divided in 4 categories:

1. Study selection (including PRISMA flowchart)
2. Overview of existing guidelines
3. Overview of included studies and qualitative results per category
4. Quantitative results

Results

Study selection

The following results were obtained:

- The PUBMED SEARCH: ((head and neck cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (imaging[Title/Abstract]) resulted in 133 hits. After exclusion of records obviously not covering the topic of the review, 91 records remained (Manuscript selection sheet, column B).
- The PUBMED SEARCH: ((head and neck cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (posttreatment[Title/Abstract]) resulted in 101 hits. After exclusion of records obviously not covering the topic of the review and duplicates, 69 records remained (Manuscript selection sheet, column C).
- References in NCCN guidelines: 6 records selected (Manuscript selection sheet, column D).
- The PUBMED SEARCH: ((head and neck cancer[Title/Abstract]) AND (follow-up[Title/Abstract])) AND (posttreatment[Title/Abstract]) resulted in 244 hits. After exclusion of records obviously not covering the topic of the review and duplicates, 74 records remained (Manuscript selection sheet, column E).
- The PUBMED SEARCH: ((head and neck cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (tomography[Title/Abstract]) resulted in 70 hits. After exclusion of records obviously not covering the topic of the review and duplicates, 50 records remained (Manuscript selection sheet, column F).
- The PUBMED SEARCH: (((cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (imaging[Title/Abstract])) AND (pharynx) resulted in 10 hits. After exclusion of records obviously not covering the topic of the review and duplicates, 3 records remained (Manuscript selection sheet, column G).

- The PUBMED SEARCH: (((cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (imaging[Title/Abstract])) AND (oral cavity[Title/Abstract]) resulted in 20 hits. After exclusion of records obviously not covering the topic of the review and duplicates, 8 records remained (Manuscript selection sheet, column H).
- The PUBMED SEARCH: (((cancer[Title/Abstract]) AND (surveillance[Title/Abstract])) AND (imaging[Title/Abstract])) AND (larynx[Title/Abstract]) resulted in 8 hits. After exclusion of records obviously not covering the topic of the review and duplicates, 2 records remained (Manuscript selection sheet, column I).
- The GOOGLE SCHOLAR SEARCH: "head and neck cancer posttreatment imaging surveillance": resulted in 20,400 hits. The first 350 hits were checked. After exclusion of records obviously not covering the topic of the review and duplicates, 105 records remained (Manuscript selection sheet, column J, marked with "1").
- The GOOGLE SCHOLAR SEARCH: "head and neck cancer posttreatment imaging follow-up": resulted in 23,800 hits. The first 100 hits were checked. After exclusion of records obviously not covering the topic of the review and duplicates, 4 records remained (Manuscript selection sheet, column J, marked with "2").
- The GOOGLE SCHOLAR SEARCH: "pharynx cancer imaging surveillance": resulted in 15,000 hits. The first 100 hits were checked. After exclusion of records obviously not covering the topic of the review and duplicates, 8 records remained (Manuscript selection sheet, column J, marked with "3").
- The GOOGLE SCHOLAR SEARCH: "oral cavity cancer imaging surveillance": resulted in 46,700 hits. The first 100 hits were checked. After exclusion of records obviously not covering the topic of the review and duplicates, 12 records remained (Manuscript selection sheet, column J, marked with "4").
- The GOOGLE SCHOLAR SEARCH: "larynx cancer imaging follow-up surveillance": resulted in 25,300 hits. The first 100 hits were checked. After exclusion of records obviously not covering the topic of the review and duplicates, 16 records remained (Manuscript selection sheet, column J, marked with "5").
- The GOOGLE SCHOLAR SEARCH: "head and neck cancer tomography surveillance": resulted in 66,900 hits. The first 100 hits were checked. After exclusion of records obviously not covering the topic of the review and duplicates, 7 records remained (Manuscript selection sheet, column J, marked with "6").

- The GOOGLE SCHOLAR SEARCH: "cited by": for every article, a search through Google Scholar was conducted looking for (newer) articles that cite the initially found articles in their reference list ("cited by"). After exclusion of records obviously not covering the topic of the review and duplicates, 182 records remained (Manuscript selection sheet, column K).
- UPTODATE: Also was checked if the database "UpToDate" contained additional information or references. Eight new records were found (Manuscript selection sheet, column L).

In total, 521 records were identified through database search. In addition, 44 additional records were identified through other sources.

In total, 565 records were screened on basis of title and abstract. From these, 432 records were excluded. Reasons for exclusion were as follows: letters, review papers, editorials, case reports, studies on tumor types other than squamous cell carcinoma, tumors in locations other than nasopharynx, oropharynx, hypopharynx, larynx, or oral cavity, articles focusing on the first post-treatment scan (typically performed after 3–6 months), articles focusing on diagnosis, staging or treatment, articles failing to provide a comparison between systematic imaging-based surveillance and surveillance directed by symptoms and/or clinical/endoscopic exam, articles with methodological errors or missing information, articles in languages other than English, French, or Dutch, and articles published before 2000.

Thus, 133 (565 minus 432) records were promoted to the next step in the review process: assessment of full-text articles (Manuscript selection sheet, column M, marked with "x"). From these 133 articles, 85 were excluded for one or more of the above given reasons. So, 48 articles were selected for the final review (Manuscript selection sheet, column N, marked with "x").

The process is summarized in Fig. 1.

Overview of existing guidelines

An overview of existing international guidelines regarding surveillance imaging after the initial (3–6 months) post-treatment baseline imaging study are given in Table 1.

- As shown in Table 1, nine different guidelines were found during full text search of the selected articles. All guidelines support the use of initial (3–6 months) post-treatment imaging. However, subsequent imaging recommendations for asymptomatic patients span the spectrum from no routine imaging to regular periodic imaging.
- During our search, we found that many papers refer to the NCCN guidelines. In these guidelines, imaging after the first post-treatment scan is recommended only in locoregionally advanced disease

Table 1 Overview of existing international guidelines with regard to surveillance imaging after the initial (3–6 months) post-treatment baseline imaging study

Organization	Year	Guidelines
NCCN [8]	2022	• Imaging only in locoregionally advanced disease and only if clinically indicated • PET-CT may be the most sensitive imaging modality • If a PET/CT at 3 months post-treatment is negative, there are no data to support substantial benefit for further routine imaging in an asymptomatic patient with negative clinical exam • Routine annual imaging (repeat use of pretreatment imaging modality) may be indicated to visualize areas inaccessible to routine clinical examination (deep-seated anatomic locations or areas obscured by extensive treatment change)
eviCore 2.1 Clinical Guidelines [10]	2021	• No imaging surveillance after first post-treatment scan • Exceptions: in case of nasopharyngeal primary site or physical exam unable to visualize deep-seated primary site: annual CT or MRI for 3 years • In smokers: CT chest only if lung cancer screening criteria are met
AWMF (Germany) [11]	2012	• Imaging every 6 months in the first and second year, every 12 months in years 3–5
BAHNO (UK) [12]	2001	• None (symptom-directed only)
EHNS-ESMO-ESTRO [15]		• Imaging should be carried out if symptoms occur or in cases of abnormalities found at the clinical examination
ASCO [13]	2019	• Only if initial PET-CT shows possibly suspect lymph node
AHNS [16]	2016	• Consider in case of smoking history, nasopharyngeal primary, or tumor site inaccessible to clinical examination • Endorses NCCN guidelines
NI-RADS [17]	2018	• CT, MRI, or PET-CT every 3, 6, or 12 months depending on initial post-treatment imaging findings
ACS [14]	2016	• No definite recommendations

and only if clinically indicated (symptomatic patient or suspect clinical finding). A possible exception to this general rule may be the post-treatment assessment of areas inaccessible to routine clinical examination (deep-seated anatomic locations or areas obscured by extensive treatment change). The NCCN guidelines also suggest that PET-CT may be the most sensitive imaging modality [8].

- While several guidelines [10, 12, 15, 16] follow the general NCCN preference for non-systematic symptom-directed imaging and/or clinical finding-directed imaging, some propose a clearly different approach. AWMF, for instance, recommends CT scan of the head and neck region every 6 months in the first 2 years after treatment and every 12 months for the third to fifth years [11]. The most intensive recommendations come from NI-RADS, which advocates (at minimum) annual surveillance imaging with more frequent studies for concerning or equivocal findings [17]. The NI-RADS approach makes follow-up strategies dependent on initial imaging findings. NI-RADS provides a structured reporting template and suggests classifying imaging findings in one of four categories: NI-RADS 1 (no evidence of recurrence), NI-RADS 2 (low suspicion, defined as ill-defined non-mass-like areas(s) of soft tissue with only mild differential enhancement or mild fluorine-18–2-fluoro-2-deoxy-D-glucose (FDG) uptake), NI-RADS 3 (high suspicion), and NI-RADS 4 (definite recurrence).

Overview of included studies and summarized qualitative results per category

Tables 2, 3, 4, and Supplementary Tables 1 and 2 provide an overview of the studies that were selected for qualitative review in one of the following categories:

- Head and neck cancer in general (Table 2)
- Oropharyngeal cancer (Table 3)
- Cancer of the oral cavity (Table 4)
- Cancer of the hypopharynx/larynx (Supplementary Table 1)
- Results for comparison of imaging techniques (Supplementary Table 2)

Summary of results for head and neck cancer in general (Table 2)

- A large majority (18/25) of reports analyzed in this study suggest that systematic post-treatment surveil-

lance imaging may be useful in terms of additional lesion detection when compared to a strategy where imaging is reserved for cases with suspect symptoms or clinical findings.

- In 11/17 studies with positive results, PET-CT was (predominantly or exclusively) used as imaging modality (65%). The average publication year of the studies with positive results was 2015. In 1/4 studies with negative results, PET-CT was (predominantly or exclusively) used as imaging modality (25%). The average publication year of the studies with positive results was 2013. In other words, there is a tendency toward better results in recently published studies using PET-CT as imaging modality.
- Most authors agree that imaging screening after 2 years is probably not effective. Several authors suggest performing surveillance imaging (mainly PET-CT) at 1 or 2 time points after the initial post-treatment scan. Suggested regimens are PET-CT exams at 12 months [41], 12 and 24 months [40], 9 months [33], 12 months [36], 12 months and 18–24 months [32], 18 months [42], 8 and 14 months [38], and 24 months [39].
- Of particular interest is the report of McDermott et al. [38]. These authors showed that a single PET-CT with negative findings carries a NPV of 91%, which the authors consider insufficient to defer further radiologic surveillance. On the other hand, two consecutive PET-CT examinations with negative findings within a 6-month period, resulted in an NPV of 98%, which could obviate further radiologic imaging in the absence of clinical signs of recurrence.

Summary of results for oropharyngeal cancer (Table 3)

Only five reports focused exclusively on oropharyngeal cancer (OPC). The results for oropharyngeal cancer are more mixed than those for the larger group of head and neck cancers. Among other factors, this may be related to the fact that this group contains both HPV-positive (HPV+) and HPV-negative (HPV−) OPCs, which have a quite distinct clinical behavior and prognosis.

Summary of results for cancer of the oral cavity (Table 4)

- As in the studies summarized in Table 2 (general group), most reports on oral cavity cancer Imaging surveillance (at least once) after 3–6 months appears to be beneficial in terms of lesion detection. Also, imaging surveillance after 2 years post-treatment appears to be less effective.
- When a free or pedicled flap reconstruction is required, a certain degree of distortion of the ana-

Table 2 Post-treatment imaging of head and neck cancer beyond the first 3–6-month baseline imaging study. Overview of included studies evaluating the results obtained with routine imaging surveillance versus symptom-directed imaging and/or clinical finding-directed imaging

First author and year	Imaging technique(s)	Design/methods	Results/conclusion
Imaging surveillance (at least once) after 3–6 months appears to be beneficial (in terms of lesion detection)			
Alnefaie 2022 [25]	RX/CT (lung)	• Nationwide cross-sectional survey	• Pulmonary screening is believed to be very effective or somewhat effective
Ng 2020 [26]	mixed	• Markov decision process model	• For an infinite horizon policy, optimal scan intervals were between 10 and 18 months
Gore 2020 [27]	CT/PET-CT	• Retrospective study including 255 patients	• Imaging surveillance beyond the first posttreatment baseline study was critical for detecting clinically occult recurrent disease (36% of all recurrences)
Ng 2019 [28]	mixed	• Retrospective study including 1508 patients • Disease recurrences were classified as either clinically detected or imaging-detected	• 20% of patients with locoregional recurrence and 60% of distant recurrences did not present with a clinical finding and were detected by imaging • The yield of detecting a salvageable recurrence with routine imaging after 2 years in an asymptomatic patient with no adverse clinical findings is extremely low
Iovoli 2018 [29]	CT (lung)	• Retrospective study including 1114 patients	• Routine surveillance for HNSCC patients with lung CT imaging had value • Routine head and neck CT scans failed to identify any successfully salvaged patients
Jackowska 2018 [30]	mixed	• Retrospective study including 438 patients	• Routine imaging studies detected 25.9% of recurrences • 40.8% of recurrences were observed > 2 years after treatment
Meregaglia 2018 [31]	mixed	• Decision-analytic Markov model	• An intensive follow-up (comprising imaging tests twice a year in the first 2 years) appears cost-effective
Kim 2017 [32]	PET-CT	• Prospective study including 278 consecutive patients	• Posttreatment 18F-FDG PET/CT surveillance helped to properly detect recurrence and to predict survival • Median time to recurrence was 10 months
Kikuchi 2015 [33]	PET-CT	• Retrospective study including 158 patients	• 67% of tumor recurrences, including second primary cancers, were detected by routine surveillance with PET/ CT • PET/CT after the second scan (i.e., > 6–12 months after treatment) may be less effective
Jung 2014 [34]	CT/MRI/US	• Retrospective study including 520 patients	• 22.8% of recurrences were detected by screening imaging studies
Dunsky 2013 [35]	PET-CT	• Retrospective study including 123 patients	• 8% of PET-CT surveillance scans showed asymptomatic recurrence, at an average interval of 35.7 weeks posttreatment • Asymptomatic lesions were detected most frequently at distant sites
Kim 2013 [36]	PET-CT	• Retrospective study including 143 patients	• PET/CT is a useful tool for the detection of recurrent tumors at 3–6 and 12 months after curative treatment
Kostakoglu 2013 [37]	PET-CT	• Retrospective study including 99 patients	• FDG-PET/HRCT detected more disease recurrences or second primary cancers and did so earlier than CT or physical examination/endoscopy
McDermott 2013 [38]	PET-CT	• Retrospective study including 512 patients	• A single PET/CT with negative findings carries a NPV of 91%, which is not adequate to defer further radiologic surveillance • Two consecutive PET/CT examinations with negative findings within a 6-month period resulted in a NPV of 98%
Paidpally 2013 [39]	PET-CT	• Retrospective study including 134 patients	• PET/CT performed between 4 and 24 months after treatment adds value to clinical assessment

Table 2 (continued)

First author and year	Imaging technique(s)	Design/methods	Results/conclusion
Beswick 2012 [40]	PET-CT	• Retrospective study including 388 patients	• For patients without clinical signs of recurrence, routine PET/CT surveillance beyond the first 24 months may be of limited value
Abgral 2009 [41]	PET-CT	• Prospective study including 91 patients	• PET/CT is more accurate than conventional follow-up physical examination alone • PET/CT could be proposed systematically at 12 months of the usual follow-up
Lee 2007 [42]	PET-CT	• Retrospective study including 159 patients	• For routine surveillance, the initial PET scan should be performed within 6 months after completion of treatment • The proper timing of next routine PET scan for subclinical patient with initial negative PET result might be 1 year after initial PET scan
Imaging surveillance after 3-6 m appears to have no or only limited benefit			
Iovoli 2018 [29]	CT	• Retrospective study including 534 patients	• Routine surveillance for HNSCC patients with lung CT imaging had value but routine head and neck CT scans failed to identify any successfully salvaged patients
Ho 2013 [43]	PET-CT	• Retrospective study including 1114 patients	• HNC patients with negative 3-month imaging appear to derive limited benefit from subsequent PET/CT surveillance
Sullivan 2010 [44]	CT	• Retrospective cohort study including 131 patients	• The utility of CT for surveillance may be limited
Saussez 2007 [45]	RX/US/CT	• Retrospective cohort study including 195 patients	• Systematic head and neck US and CT exams revealed recurrent cancers with poor efficiency and should be performed only after clinical suspicion of recurrence
Imaging surveillance after 3-6 m is of uncertain benefit/other			
Zhang 2011 [46]	PET-CT	• Retrospective cohort study including 62 patients	• A negative initial posttreatment PET/CT result may have the potential to identify patients who are at very low risk of recurrence • The HPV status may augment the predictive utility of an initial negative PET/CT result

Table 3 Post-treatment imaging of oropharyngeal cancer beyond the first 3–6-month baseline imaging study. Overview of included studies evaluating the results obtained with routine imaging surveillance versus symptom-directed imaging and/or clinical finding-directed imaging

First author and year	Imaging technique(s)	Design/methods	Results
Imaging surveillance (at least once) after 3–6 months appears to be beneficial (in terms of lesion detection)			
Nair 2022 [47]	CT	• Markov model based on data of 2159 patients	• Optimized, risk-stratified surveillance regimens consistently outperformed nonoptimized strategies. Best results were obtained with use of 6 post-treatment scans
Su 2018 [48]	PET-CT	• Retrospective cohort study including 33 patients	• In HPV+ patients, a large proportion of failures are asymptomatic distant metastases, which occur beyond 6 months following treatment completion, and are detected with whole body imaging alone
You 2018 [49]	PET-CT	• Retrospective cohort study including 149 patients	• PET-CT in the last 18 months of the 2-year posttreatment period impacted patient management
Imaging surveillance after 3-6 m appears to have no or only limited benefit			
Corpman 2018 [50]	PET-CT	• Retrospective study including 233 patients	• For HPV+ patients, surveillance PET-CTs frequently lead to unnecessary testing and rarely to meaningful disease salvage
Kangelaris 2010 [51]	MRI	• Retrospective study including 40 patients	• In oropharyngeal cancer patients who have been treated with chemoradiation, an imaging surveillance program utilizing MRI produces limited opportunity for successful salvage

Table 4 Post-treatment imaging of oral cavity cancer beyond the first 3–6-month baseline imaging study. Overview of included studies evaluating the results obtained with routine imaging surveillance compared to symptom-directed imaging and/or clinical finding-directed imaging

First author and year	Imaging technique(s)	Design/methods	Results
Imaging surveillance (at least once) after 3–6 months appears to be beneficial (in terms of lesion detection)			
Fukumoto 2021 [52]	CT/PET-CT	• Retrospective study including 324 patients	• It is desirable to perform PET/CT within 3–6 months and at 1 year after surgery and to consider CECT as an option in between PET/CT
Liu 2021 [53]	CT/MRI	• Retrospective study including 741 patients	• 19.7% of recurrences were found during routine imaging only • In late-stage and elderly patients, frequent head and neck CT/MRI scan was associated with a better prognosis
Ravanelli 2021 [54]	PET-CT	• Retrospective observational study including 87 patients	• Performing imaging studies every 6 months for 2 years changed the diagnostic/therapeutic strategy in about one-fifth of patients
Chi 2020 [55]	(?)	• Retrospective study including 83 patients	• 29.4% of recurrences were detected by serial imaging alone in asymptomatic patients; most of them (92.3%) occurred within the first 2 years
Lin 2017 [56]	PET-CT	• Retrospective study including 111 patients	• Scheduled periodic PET/CT surveillance is a valuable tool for early detection of recurrent lesion(s) in asymptomatic OSCC patients who bear risk factors for disease recurrence
Peisker 2017 [57]	RX/CT	• Retrospective study including 228 patients	• The results of this study suggest an intensified imaging follow-up within the first 2 years after surgery
Rivelli 2011 [58]	CT	• Retrospective study including 294 patients	• Routine CT for follow-up is indicated for detecting lymph node metastases as well as local recurrence
Imaging surveillance after 3–6 months appears to have no or only limited benefit			
Al-Shwaiheen 2014 [59]	MRI	• Retrospective study including 62 patients	• Routine MRI after 6 months may be unnecessary in patients without concurrent suspicious symptoms or exam findings
Imaging surveillance after 3-6 m is of uncertain benefit/other			
Krabbe 2009 [60]	PET-CT	• Prospective study including 48 patients	• PET is a suitable routine posttreatment surveillance tool and detects malignancy before clinical suggestion by the regular follow-up arises • The best timing of a systematic PET scan is between 3 and 6 months after treatment

tomical configuration of the residual hemitongue and floor of mouth is often produced, and clinical detection of recurrence may be difficult. It is not surprising that, in such cases, data show superior results with systematic imaging surveillance.

Summary of results for cancer of the hypopharynx/larynx (Supplementary Table 1)

- Only a limited number of studies is available for this body part. Submucosal recurrence appears to be an important issue, making imaging surveillance mandatory [61, 62].

Summary of results for comparison of imaging techniques (Supplementary Table 2)

- In this category, PET-CT appears to be the preferred modality for imaging surveillance [63–70]. Depending on the specific case (e.g., location of recurrence), MRI may be useful for confirmation and additional staging.

Quantitative results
The quantitative results of the different studies are summarized in Table 5.

Table 5 Post-treatment imaging of head and neck cancer beyond the first 3–6-month baseline imaging study. Percentage of recurrences detected with surveillance imaging only, percentage recurrences after 6 months, and time to recurrence

First author and year	Location	% Recurrence only detected with imaging	% Recurrence after 6 months	Median time to recurrence (months)	Time to recurrence: range
Ng 2019 [26]	Mixed	38		12.5	(1–160)
Gore 2019 [27]	Mixed	36		11.4	
Jackowska 2018 [30]	Mixed	25.9	x		
Kim 2017 [32]	Mixed	47		10	(2–32)
Kikuchi 2015 [33]	Mixed	67	15	7.9	(1.3–78)
Jung 2014 [34]	Mixed	23	x		
Dunsky 2013 [35]	Mixed	20	64	9	(1–25)
Kim 2013 [36]	Mixed	86	33	11	(2–30)
Kostakoglu 2013 [37]	Mixed	84	50	6	(2.3–32)
Paidpally 2013 [39]	Mixed	21			
Beswick 2012 [40]	Mixed	66	55	6	(2–43)
Abgral 2009 [41]	Mixed	30	x	10.7	(1.3–20)
Lee 2007 [42]	Mixed	26	55		
Iovoli 2018 [29]	Mixed	50	x		
Ho 2013 [43]	Mixed	6	x	12	
Saussez 2007 [45]	Mixed	10			
Average mixed		**39.7**	**45.3**	**9.7**	
Su 2018 [48]	Oropharynx	84	91		
You 2018 [49]	Oropharynx		52.9		
Corpman 2018 [50]	Oropharynx	48		15	(7–24)
Kangelaris 2010 [51]	Oropharynx	50		15	(4–40)
Average OP		**60.7**	**72.0**	**15.0**	
Fukumoto 2021 [52]	Oral cavity			11.5	
Ravanelli 2021 [54]	Oral cavity	22			
Chi 2020 [55]	Oral cavity	29.4			
Lin 2017 [56]	Oral cavity	54		9.3	
Peisker 2017 [57]	Oral cavity	43.1			
Rivelli 2011 [58]	Oral cavity	16		21.7	(1–43)
Krabbe 2009 [60]	Oral cavity			7.2	
Average OC		**32.9**		**12.4**	
Marchi 2017 [62]	Hypopharynx/larynx			20	(8–60)
Average all together		**40.9**	**52.0**	**11.5**	

Summary of the quantitative results on recurrences (Table 5)

- For all records together, in summary, 40.9% locoregional recurrences and/or metastases were detected by routing post-treatment surveillance imaging and not by symptoms or clinical/endoscopic exam. Moreover, 52% of locoregional recurrences and/or metastases are detected after 6 months post-treatment, and the average time of detection of recurrent or metastatic disease is 11.5 months.
- Comparable results are obtained in the subcategories, except for oropharynx. For oropharynx,

locoregional recurrences and/or metastases were detected by routine post-treatment surveillance imaging (and not by symptoms or clinical/endoscopic exam) in 60.7% versus 40.9% for the entire group. Moreover, the average time of detection of recurrent or metastatic disease was 15 months versus 11.5 months. In other words, imaging appears to be even more important in patients with treated oropharyngeal cancer (which may be related to the detection of asymptomatic distant metastases), and recurrences/metastases disease tend to occur later in time.

Discussion

Need for systematic imaging surveillance

Currently, there are no prospective randomized studies showing that systematic post-treatment surveillance imaging of patients with treated head and neck cancer is beneficial in terms of survival (with the exception of the first post-treatment study, see the "Introduction" section).

However, a large majority (18/25) of reports analyzed in this study suggest that systematic post-treatment surveillance imaging is useful in terms of additional lesion detection when compared to a strategy where imaging is reserved for cases with suspect symptoms or clinical findings. In 40.9% of cases, locoregional recurrences and/or metastases were detected by routine post-treatment surveillance imaging and not by symptoms or clinical/endoscopic exam. Thus, this systematic review provides strong arguments in favor of systematic post-treatment imaging surveillance beyond the first post-treatment scan.

This is not surprising for several reasons. First, in some anatomical locations (nasopharynx, subglottis, etc.), tumor detection and/or evaluation of submucosal spread may be difficult by clinical exam/direct inspection only. Second, tissue fibrosis, oedema, necrosis, and anatomic changes after radiotherapy and/or surgery can interfere with early detection of residual viable tumor or recurrence by the usual sequential physical and endoscopic examinations [71]. Third, a free or pedicled flap reconstruction may be required in patients with oral cavity cancer, often precluding the detection of submucosal relapse [54].

Duration of systematic imaging surveillance

Another debated topic is the optimal length of post-treatment surveillance. Our results show that, on average, 52% of locoregional recurrences and/or metastases were detected after 6 months post-treatment, and the mean time of detection of recurrent or metastatic disease was 11.5 months. These numbers give strong arguments in favor of routine imaging surveillance during at least 1 (and preferably 2) year post-treatment. As suggested by others, routine surveillance imaging beyond the first 24 months may be of limited value and may not be cost effective [8, 40].

The case of oropharyngeal cancer

The discussion about the usefulness of post-treatment surveillance in oropharyngeal cancer is complicated by the fact that HPV+ and HPV- OPCs can be considered as two different disease entities. The behavior of HPV+ poses an extra challenge for surveillance: on the one hand, HPV+ patients with OPC have better outcomes, a lower risk of recurrence and metastatic disease [72], and a longer overall survival, thus apparently making post-treatment surveillance less useful. On the other hand, recurrences in HPV+ OPC tend to occur later in time, and often correspond to distant metastases detected with whole body imaging only [48], thus providing theoretical arguments for prolonged screening with imaging. The peculiar behavior of oropharyngeal cancer was also observed in our study: in comparison with other head and neck cancers, oropharyngeal recurrences and/or metastases were detected later in time (15 months versus 11.5 months) and more exclusively by imaging (60.7%, versus 40.9% for the entire group).

Recently, promising results have been obtained with plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV+ oropharyngeal cancer [73, 74]. This type of tests could possibly be used for post-treatment surveillance in HPV+ patients, whereby the role of imaging could potentially be limited to confirmation of suspect cases.

Imaging techniques for surveillance

Concerning the choice of imaging technique for post-treatment surveillance, we found better results with PET-CT when compared to CT or MRI. Treatment with radiotherapy and surgery causes inflammation, scarring, and tissue distortion, which can hinder the interpretation of anatomic imaging techniques such as CT and MRI. The metabolic information provided by 18F-FDG PET-CT allows it to serve as an effective tool for detecting recurrence, regional lymphatic spread, and distant metastases [39]. However, PET scanning is quite costly and may lead to additional diagnostic evaluation to rule out false positive results. As an alternative to PET-CT and depending on institutional preference, contrast-enhanced CT or MRI can be used for locoregional surveillance and low-dose CT for detection of metastatic lung disease [8]. MRI may also be useful for confirmation in case equivocal findings are found with PET-CT or for optimal assessment of specific anatomical areas (e.g., nasopharynx) [75].

Overall conclusion

This systematic review focuses on the importance of systematic post-treatment imaging surveillance beyond the initial post-treatment scan in patients with head and neck cancer. While most current guidelines do not recommend post-treatment surveillance beyond the first post-treatment scan, we found strong arguments in favor of this approach.

Our data show that almost half of cases of locoregional recurrences and/or metastases were only detected by imaging (40.9%), and the mean time of detection of

recurrent or metastatic disease (11.5 months) was well beyond the first post-treatment scan (3–6 months). As a result, we conclude that systematic imaging surveillance during at least 1 and possibly 2 years in the post-treatment period, with PET-CT being the preferred imaging modality, appears to be justified in cases of advanced head and neck cancer.

The further development of consensus guidelines regarding the surveillance of head and neck cancer by imaging methods would help to standardize the follow-up of these patients in the most effective way possible, with the goal of improving the eventual treatment outcome. This should ideally be done under the guidance of recognized organizations in the field.

Abbreviations

ACS	American Cancer Society
ASCO	American Society of Clinical Oncology
AWMF	Association of Scientific Medical Societies in Germany
HNSCC	Head and neck squamous cell carcinomas
HPV	Human papilloma virus
NCCN	National Comprehensive Cancer Network
NI-RADS	Neck imaging reporting and data system
NPV	Negative predictive value
OC	Oral cavity
OP	Oropharynx
OPC	Oropharyngeal cancer
RX	Radiography

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13244-023-01578-4.

Additional file 1: Supplementary Table 1. Post-treatment imaging of cancer of the hypopharynx/larynx beyond the first 3–6-month baseline imaging study. Overview of included studies evaluating the results obtained with routine imaging surveillance compared to symptom- and/or clinical finding- directed imaging. **Supplementary Table 2.** Post-treatment imaging of head and neck cancer beyond the first 3–6-month baseline imaging study. Comparison of imaging techniques.

Additional file 2: Manuscript selection sheet.

Availability of data and materials
See Supplementary Table 3.

Declarations

Ethics approval and consent to participate
Ethical approval was waived by the University Hospitals Leuven and KU Leuven's Research Ethics Committee and The Educational Supervisory Committee on Medical Ethics.

Consent for publication
Not applicable.

Competing interests
RH is Emeritus Editor of Insights into Imaging. He has not taken part in the review or selection process of this article.
The authors declare that they have no financial or non-financial competing interests.

Author details
¹Faculty of Medicine, KU Leuven, Leuven, Belgium. ²Department of Radiology, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium. ³Department of Imaging and Pathology, KU Leuven-University of Leuven, Leuven, Belgium.

References

1. Stenson K, Brockstein B, Ross M (2023) Epidemiology and risk factors for head and neck cancer. In: UpToDate, Post TW (Ed), Wolters Kluwer (accessed on January 15, 2023)
2. Nissi L, Suilamo S, Kyto E, Vaittinen S, Irjala H, Minn H (2021) Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume. Clin Transl Radiat Oncol 27:139–146
3. Agarwal V, Branstetter B, Johnson J (2008) Indications for PET/CT in the head and neck. Otolaryngol Clin North Am 41:23–49
4. Pisani P, Airoldi M, Allais A et al (2020) Metastatic disease in head & neck oncology. Acta Otorhinolaryngol Ital 40:S1–S86
5. Leon X, Quer M, Diez S et al (1999) Second neoplasm in patients with head and neck cancer. Head Neck 21:204–210
6. Atienza JA, Dasanu CA (2012) Incidence of second primary malignancies in patients with treated head and neck cancer: a comprehensive review of literature. Curr Med Res Opin 28:1899–1909
7. Isles MG, McConkey C, Mehanna HM (2008) A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 33:210–222
8. Pfister DG, Spencer S, Adelstein D et al (2022) Head and neck cancers, version 2.2022, NCCN clinical practice guidelines in oncology
9. You H, Subramaniam RM (2022) PET/computed tomography: post-therapy follow-up in head and neck cancer. PET Clin 17:319–326
10. EviCore 2.1 Clinical Guidelines. Oncology Imaging Policy 2020. https://www.evicore.com/-/media/files/evicore/clinical-guidelines/solution/cardiology-and-radiology/2020/evicore_oncology_final_v21_eff100120_pub100120.pdf
11. Wolff KD, Follmann M, Nast A (2012) The diagnosis and treatment of oral cavity cancer. Dtsch Arztebl Int 109:829–835
12. British Association of Head and Neck Oncologists (2001) Practice care guidance for clinicians participating in the management of head and neck cancer patients in the UK. Drawn up by a Consensus Group of Practising Clinicians. Eur J Surg Oncol 27:1–17
13. Koyfman S, Ismaila N, Crook D et al (2019) Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: ASCO clinical practice guideline. J Clin Oncol 37:1753–1774
14. Cohen E, LaMonte S, Erb N et al (2016) American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin 66:203–239
15. https://www.esmo.org/guidelines/guidelines-by-topic/head-and-neck-cancers
16. Roman BR, Goldenberg D, Givi B (2016) AHNS series: do you know your guidelines? Guideline recommended follow-up and surveillance of head and neck cancer survivors. Head Neck 38:168–174
17. Aiken A, Rath T, Anzai Y et al (2018) ACR Neck Imaging Reporting and Data Systems (NI-RADS): a white paper of the ACR NI-RADS committee. J Am Coll Radiol 15:1097–1108
18. Gill A, Vasan N, Givi B, Joshi A (2018) AHNS Series: Do you know your guidelines? Evidence-based management of oral cavity cancers. Head Neck 40:406–416

19. Ng SP, Ajayi T, Schaefer AJ et al (2020) Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: a partially observed Markov decision process model. Cancer 126:749–756
20. Roman B, Patel S, Wang M et al (2015) Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer. J Natl Compr Canc Netw 13:69–77
21. Nocon CC, Kennedy A, Jaffe J, Pruitt J, Kuchta K, Bhayani MK (2021) Costs associated with imaging surveillance after treatment for head and neck cancer. JAMA Otolaryngol Head Neck Surg 147:632–637
22. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 21:6
23. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100
24. Saba NF (2023) Posttreatment surveillance of squamous cell carcinoma of the head and neck. In: UpToDate, Post TW (Ed), Wolters Kluwer (accessed on January 15, 2023)
25. Alnefaie M, Alamri A, Saeedi A et al (2022) Pulmonary screening practices of otolaryngology-head and neck surgeons across Saudi arabia in the posttreatment surveillance of squamous cell carcinoma: cross-sectional survey study. Interact J Med Res 18:e24592
26. Ng SP, Ajayi T, Schaefer AJ et al (2020) Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: a partially observed Markov decision process model. Cancer 126:749–756
27. Gore A, Baugnon K, Beitler J et al (2020) Posttreatment imaging in patients with head and neck cancer without clinical evidence of recurrence: should surveillance imaging extend beyond 6 months? AJNR Am J Neuroradiol 41:1238–1244
28. Ng SP, Pollard C, Berends J et al (2019) Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer 125:1823–1829
29. Iovoli AJ, Platek AJ, Degraaff L et al (2018) Routine surveillance scanning in HNSCC: Lung screening CT scans have value but head and neck scans do not. Oral Oncol 86:273–277
30. Jackowska J, Abelak Y, Piersiala K, Wierzbicka M (2018) The effectiveness of the follow-up of patients after surgery due to cancer of the head and neck. J Comp Eff Res 7:765–773
31. Meregaglia M, Cairns J, Licitra L, Bossi P (2018) The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: an economic evaluation. Eur J Cancer 93:89–98
32. Kim SA, Roh JL, Kim JS et al (2017) 18F-FDG PET/CT surveillance for the detection of recurrence in patients with head and neck cancer. Eur J Cancer 72:62–70
33. Kikuchi M, Shinohara S, Hino M et al (2016) Detection of subclinical recurrence or second primary cancer using (18) F-FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma. Head Neck 38(Suppl 1):E511–E518
34. Jung YH, Song CM, Park JH et al (2014) Efficacy of current regular follow-up policy after treatment for head and neck cancer: need for individualized and obligatory follow-up strategy. Head Neck 36:715–721
35. Dunsky KA, Wehrmann DJ, Osman MM, Thornberry BM, Varvares MA (2013) PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient. Laryngoscope 123:2161–2164
36. Kim JW, Roh JL, Kim JS et al (2013) (18)F-FDG PET/CT surveillance at 3–6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma. Br J Cancer 109:2973–2979
37. Kostakoglu L, Fardanesh R, Posner M et al (2013) Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. Oncologist 18:1108–1117
38. McDermott M, Hughes M, Rath T et al (2013) Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer. AJNR Am J Neuroradiol 34:1632–1636
39. Paidpally V, Tahari AK, Lam S et al (2013) Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. J Nucl Med 54:2039–2045
40. Beswick DM, Gooding WE, Johnson JT, Branstetter BF (2012) Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring. Laryngoscope 122:1512–1517
41. Abgral R, Querellou S, Potard G et al (2009) Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 50:24–29
42. Lee JC, Kim JS, Lee JH et al (2007) F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol 43:686–692
43. Ho AS, Tsao GJ, Chen FW et al (2013) Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer 119:1349–1356
44. Sullivan BP, Parks KA, Dean NR, Rosenthal EL, Carroll WR, Magnuson JS (2011) Utility of CT surveillance for primary site recurrence of squamous cell carcinoma of the head and neck. Head Neck 33:1547–1550
45. Saussez S, Dekeyser C, Thill MP, Chantrain G (2007) Importance of clinical and radiological follow-up in head and neck cancers. B-ENT 3:179–184
46. Zhang I, Branstetter BF, Beswick DM, Maxwell JH, Gooding WE, Ferris RL (2011) The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 137:1106–1111
47. Nair V, Auger S, Kochanny S et al (2022) Development and validation of a decision analytical model for posttreatment surveillance for patients with oropharyngeal carcinoma. JAMA Netw Open 5:e227240
48. Su W, Miles BA, Posner M, et al. (2018) Surveillance imaging in HPV-related oropharyngeal cancer. Anticancer Res 38:1525–1529
49. You H, Xi Y, Moore W, Sher D, Sanli Y, Subramaniam RM (2019) Timing and impact of posttreatment PET/CT after first 6 months on patient management and outcomes in oropharyngeal squamous cell carcinoma. AJR Am J Roentgenol 5:1–6
50. Corpman DW, Masroor F, Carpenter DM, Nayak S, Gurushanthaiah D, Wang KH (2019) Posttreatment surveillance PET/CT for HPV-associated oropharyngeal cancer. Head Neck 41:456–462
51. Kangelaris GT, Yom SS, Huang K, Wang SJ (2010) Limited utility of routine surveillance MRI following chemoradiation for advanced-stage oropharynx carcinoma. Int J Otolaryngol 2010:904297
52. Fukumoto C, Oshima R, Sawatani Y et al (2021) Surveillance for patients with oral cavity cancer after complete surgical resection as primary treatment: a single-center retrospective cohort study. Cancers (Basel) 13:5843
53. Liu SA, Wang CC, Jiang RS, Tung YC (2021) Less is more? The association between survival and follow-up protocol after treatment in oral cavity cancer patients from a betel quid-prevalent region. Int J Environ Res Public Health 18:12596
54. Ravanelli M et al (2021) Value of [18F] FDG PET-CT in the follow-up of surgically treated oral tongue squamous cell carcinoma: single centre cohort analysis on 87 patients. Nucl Med Rev 24:58–62
55. Chi J, Chung S, Lopez C et al (2020) The role of routine surveillance imaging in detecting oral cavity cancer recurrence in asymptomatic patients. J Clin Oncol 38(15_suppl):e18561–e18561
56. Lin HC, Kang CJ, Huang SF et al (2017) Clinical impact of PET/CT imaging after adjuvant therapy in patients with oral cavity squamous cell carcinoma. Eur J Nucl Med Mol Imaging 44:1702–1711
57. Peisker A, Raschke GF, Guentsch A, Luepke P, Roshanghias K, Schultze-Mosgau S (2017) Evaluation of a post-treatment follow-up program in patients with oral squamous cell carcinoma. Clin Oral Investig 21:135–141
58. Rivelli V, Luebbers HT, Weber FE, Cordella C, Grätz KW, Kruse AL (2011) Screening recurrence and lymph node metastases in head and neck cancer: the role of computer tomography in follow-up. Head Neck Oncol 3:18
59. Al-Shwaiheen FA, Wang SJ, Uzelac A, Yom SS, Ryan WR (2015) The advantages and drawbacks of routine magnetic resonance imaging for long-term post-treatment locoregional surveillance of oral cavity squamous cell carcinoma. Am J Otolaryngol 36:415–423
60. Krabbe CA, Pruim J, Dijkstra PU et al (2009) 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med 50:1940–1947
61. Hermans R, Pameijer FA, Mancuso AA, Parsons JT, Mendenhall WM (2000) Laryngeal or hypopharyngeal squamous cell carcinoma: can follow-up

CT after definitive radiation therapy be used to detect local failure earlier than clinical examination alone? Radiology 214:683–687

62. Marchi F, Piazza C, Ravanelli M et al (2017) Role of imaging in the follow-up of T2–T3 glottic cancer treated by transoral laser microsurgery. Eur Arch Otorhinolaryngol 274:3679–3686

63. Morgan R, Karam S (2020) Surveillance imaging of laryngeal cancer-does FDG PET/CT impact survival? J Nucl Med 61(supplement 1):1291–1291

64. House AE, Zebolsky AL, Jacobs J et al (2021) Surveillance imaging following head and neck cancer treatment and microvascular reconstruction. Laryngoscope 131:2713–2718

65. Breik O, Kumar A, Birchall J, Mortimore S, Laugharne D, Jones K (2020) Follow up imaging of oral, oropharyngeal and hypopharyngeal cancer patients: comparison of PET-CT and MRI post treatment. J Craniomaxillofac Surg 48:672–679

66. Suenaga Y, Kitajima K, Ishihara T et al (2016) FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT. Eur Radiol 26:1018–1030

67. Ichpujani VK, Rao SA, Chaturvedi AK, Dewan AK, Choudhary PS (2014) Positron emission tomography-computed tomography: a superior and one-stop shop modality for treated head and neck carcinoma compared with conventional tomography. J Oral Maxillofac Surg 72:2319–2332

68. Ghanooni R, Delpierre I, Magremanne M et al (2011) ^{18}F-FDG PET/CT and MRI in the follow-up of head and neck squamous cell carcinoma. Contrast Media Mol Imaging 6:260–266

69. Wang YF, Liu RS, Chu PY, et al. (2009) Positron emission tomography in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy. Head Neck 31:442–451

70. Fakhry N, Lussato D, Jacob T, Giorgi R, Giovanni A, Zanaret M (2007) Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications. Eur Arch Otorhinolaryngol 264:531–538

71. Salaun PY, Abgral R, Querellou S et al (2007) Does 18fluoro-fluorodeoxy-glucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck 29:1115–1120

72. Bird T, Barrington S, Thavaraj S et al (2016) (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 43:1239–1247

73. Berger BM, Hanna GJ, Posner MR et al (2022) Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma. Clin Cancer Res 28:4292–4301

74. Chera BS, Kumar S, Shen C et al (2020) Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol 38:1050–1058

75. Hermans R (2008) Posttreatment imaging in head and neck cancer. Eur J Radiol 66:501–511

Publisher's Note